Meta-analysis of randomized studies using lysergic acid diethylamide (LSD) for alcohol use disorder (AUD) showed large, significant effects for LSD efficacy compared to control conditions. Clinical studies suggest potential anti-addiction effects of LSD and mechanistically-related classic psychedelics for alcohol and other substance use disorders.
Aims:
To supplement clinical studies, reports of psychedelic use in naturalistic settings can provide further data regarding potential effects of psychedelics on alcohol use.
Methods:
An anonymous online survey of individuals with prior AUD reporting cessation or reduction in alcohol use following psychedelic use in non-clinical settings.
Results:
343 respondents, mostly White (89%), males (78%), in the USA (60%) completed the survey. Participants reported seven years of problematic alcohol use on average before the psychedelic experience to which they attributed reduced alcohol consumption, with 72% meeting retrospective criteria for severe AUD. Most reported taking a moderate or high dose of LSD (38%) or psilocybin (36%), followed by significant reduction in alcohol consumption. After the psychedelic experience 83% no longer met AUD criteria. Participants rated their psychedelic experience as highly meaningful and insightful, with 28% endorsing psychedelic-associated changes in life priorities or values as facilitating reduced alcohol misuse. Greater psychedelic dose, insight, mystical-type effects, and personal meaning of experiences were associated with a greater reduction in alcohol consumption, controlling for prior alcohol consumption and related distress.
Conclusions:
Although results cannot demonstrate causality, they suggest that naturalistic psychedelic use may lead to cessation or reduction in problematic alcohol use, supporting further investigation of psychedelic-assisted treatment for AUD.
AbuzzahabFSAndersonBJ (1971) A review of LSD treatment in alcoholism. Int Pharmacopsychiatry6: 223–235.
2.
AlbaughBJAndersonPO (1974) Peyote in the treatment of alcoholism among American Indians. Am J Psychiatry131: 1247–1250.
3.
American Psychiatric Association (1994) DSM-IV: Diagnostic and Statistical Manual of Mental Disorders. 4th ed.Washington DC: American Psychiatric Press.
4.
American Psychiatric Association (2013) Diagnostic and Statistical Manual of Mental Disorders. 5th ed.Arlington, VA: American Psychiatric Publishing.
5.
AntonRFO’MalleySSCirauloDA, et al. (2006) Combined pharmacotherapies and behavioral interventions for alcohol dependence: The COMBINE study: A randomized controlled trial. JAMA295: 2003–2017.
6.
BarbosaPCTofoliLFBogenschutzMP, et al. (2018) Assessment of alcohol and tobacco use disorders among religious users of Ayahuasca. Front Psychiatry9: 136.
7.
BarbosaPCRMizumotoSBogenschutzMP, et al. (2012) Health status of Ayahuasca users. Drug Test Anal4: 601–609.
8.
BarrettFSJohnsonMWGriffithsRR (2015) Validation of the revised Mystical Experience Questionnaire in experimental sessions with psilocybin. J Psychopharmacol29: 1182–1190.
9.
BlissDL (2008) Empirical research on spirituality and alcoholism: A review of the literature. J Soc Work Pract Addict7: 5–25.
10.
BogenschutzMPForcehimesAAPommyJA, et al. (2015) Psilocybin-assisted treatment for alcohol dependence: A proof-of-concept study. J Psychopharmacol29: 289–299.
11.
BogenschutzMPPommyJM (2012) Therapeutic mechanisms of classic hallucinogens in the treatment of addictions: From indirect evidence to testable hypotheses. Drug Test Anal4: 543–555.
12.
BohnMJKrahnDDStaehlerBA (1995) Development and initial validation of a measure of drinking urges in abstinent alcoholics. Alcohol Clin Exp Res19: 600–606.
13.
BonsonKR (2017) Regulation of human research with LSD in the United States (1949–1987). Psychopharmacology235(2): 591–604.
14.
BowenWTSoskinRAChotlosJW (1970) Lysergic acid diethylamide as a variable in the hospital treatment of alcoholism: A follow-up study. J Nerv Ment Dis150: 111–118.
15.
BradleyKADeBenedettiAFVolkRJ, et al. (2007) AUDIT-C as a brief screen for alcohol misuse in primary care. Alcohol Clin Exp Res31: 1208–1217.
16.
BushKKivlahanDRMcDonellMB, et al. (1998) The AUDIT alcohol consumption questions (AUDIT-C): An effective brief screening test for problem drinking. Arch Intern Med158: 1789–1795.
17.
CanagasabyAVinsonDC (2005) Screening for hazardous or harmful drinking using one or two quantity–frequency questions. Alcohol Alcohol40: 208–213.
18.
Carhart-HarrisRLBolstridgeMRuckerJ, et al. (2016) Psilocybin with psychological support for treatment-resistant depression: An open-label feasibility study. Lancet Psychiatry3: 619–627.
19.
Carhart-HarrisRLErritzoeDWilliamsT, et al. (2012) Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin. Proc Natl Acad Sci109: 2138–2143.
20.
Carhart-HarrisRLRosemanLBolstridgeM, et al. (2017) Psilocybin for treatment-resistant depression: fMRI-measured brain mechanisms. Sci Rep7: 13187.
21.
Carhart-HarrisRLRosemanLHaijenE, et al. (2018) Psychedelics and the essential importance of context. J Psychopharmacol. 32: 725–731.
22.
CarmenBAngelesMAnaM, et al. (2004) Efficacy and safety of naltrexone and acamprosate in the treatment of alcohol dependence: A systematic review. Addiction99: 811–828.
23.
CarrollS (1993) Spirituality and purpose in life in alcoholism recovery. J Stud Alcohol54: 297–301.
24.
Cata-PretaEGSerraYAMoreira-JuniorED, et al. (2018) Ayahuasca and its DMT- and β-carbolines – containing ingredients block the expression of ethanol-induced conditioned place preference in mice: Role of the treatment environment. Front Pharmacol9: 561.
25.
Center for Behavioral Health Statistics and Quality (2017) 2016 National Survey on Drug Use and Health: Detailed Tables. Rockville, MD: Substance Abuse and Mental Health Services Administration.
26.
Centers for Disease Control and Prevention (CDC) (2013) Alcohol Related Disease Impact (ARDI) Application. Available at: www.cdc.gov/ARDI.
27.
ChwelosNBlewettDBSmithCM, et al. (1959) Use of d-lysergic acid diethylamide in the treatment of alcoholism. Quart J Stud Alcohol20: 577–590.
28.
ClinicalTrials.gov. National Library of Medicine (U.S.) (2014a, February12). A Double-Blind Trial of Psilocybin-Assisted Treatment of Alcohol Dependence. Identifier NCT02061293. Available at: https://clinicaltrials.gov/ct2/show/NCT02061293 (accessed 12 May 2016).
29.
ClinicalTrials.gov. National Library of Medicine (U.S.) (2014b, January15). Psilocybin-facilitated Treatment for Cocaine Use. Identifier NCT02037126. Available at: https://clinicaltrials.gov/ct2/show/NCT02037126 (accessed 12 May 2018).
30.
ConnorJ (2017) Alcohol consumption as a cause of cancer. Addiction112: 222–228.
31.
CrewsFTZouJQinL (2011) Induction of innate immune genes in brain create the neurobiology of addiction. Brain Behav Immun25: S4–S12.
32.
CuiCShurtleffDHarrisRA (2014) Neuroimmune mechanisms of alcohol and drug addiction. Int Rev Neurobiol118: 1–12.
33.
DavisAKArterberryBJBonarEE, et al. (2018a) Predictors of positive treatment response among youth receiving a brief alcohol intervention in the emergency department. Drug Alcohol Depend188: 102–108. doi: 10.1016/j.drugalcdep.2018.03.044
34.
DavisAKBarsugliaJPLancelottaR, et al. (2018b) The epidemiology of 5-methoxy-N, N-dimethyltryptamine (5-MeO-DMT) use: Benefits, consequences, patterns of use, subjective effects, and reasons for consumption. J Psychopharmacol32: 779–792.
35.
DavisAKSoSLancelottaR, et al. (2019) 5-Methoxy-N, N-dimethyltryptamine (5-MeO-DMT) used in a naturalistic setting is associated with unintended improvements in depression and anxiety. Am J Drug Alcohol Ab45: 161–169.
36.
DawsonDAGrantBFStinsonFS, et al. (2005) Recovery from DSM-IV alcohol dependence: United States, 2001–2002. Addiction100: 281–292.
37.
DoblinR (1991) Pahnke’s “Good Friday Experiment”: A long-term follow-up and methodological critique. J Transpers Psychol23: 1–28.
38.
DolderPCSchmidYMüllerF, et al. (2016) LSD acutely impairs fear recognition and enhances emotional empathy and sociality. Neuropsychopharmacology41: 2638.
39.
dos SantosRGLandeira-FernandezJStrassmanRJ, et al. (2007) Effects of ayahuasca on psychometric measures of anxiety, panic-like, and hopelessness in Santo Daime members. J Ethnopharmacol112: 507–513.
40.
dos SantosRGOsórioFLCrippaJAS, et al. (2016) Antidepressive and anxiolytic effects of ayahuasca: A systematic literature review of animal and human studies. Revista Brasileira de Psiquiatria38: 65–72.
41.
DrummondDCPhillipsTS (2002) Alcohol urges in alcohol-dependent drinkers: Further validation of the Alcohol Urge Questionnaire in an untreated community clinical population. Addiction97: 1465–1472.
42.
DyckE (2006) ‘Hitting highs at rock bottom’: LSD treatment for alcoholism, 1950–1970. Soc Hist Med19: 313–329.
43.
FábregasJMGonzálezDFondevilaS, et al. (2010) Assessment of addiction severity among ritual users of ayahuasca. Drug Alcohol Depend111: 257–261.
44.
FlanaganTWNicholsCD (2018) Psychedelics as anti-inflammatory agents. Int Rev Psychiatry30(4): 363–375.
45.
Garcia-RomeuAGriffithsRRJohnsonMW (2015) Psilocybin-occasioned mystical experiences in the treatment of tobacco addiction. Curr Drug Abuse Rev7: 157.
46.
Garcia-RomeuAKersgaardBAddyPH (2016) Clinical applications of hallucinogens: A review. Exper Clin Psychopharmacol24: 229.
47.
GasserPHolsteinDMichelYDoblin, et al. (2014) Safety and efficacy of lysergic acid diethylamide-assisted psychotherapy for anxiety associated with life-threatening diseases. J Nerv Ment Dis202: 513.
48.
GodinhoAFSilvaMCKawashimaJD, et al. (2017) Ayahuasca modifies amphetamine self-ingestion and modifies anxiety and locomotor activity in adolescent rats. Electr J Biol13: 159–165.
49.
Gouzoulis-MayfrankEHeekerenKThelenB, et al. (1998) Effects of the hallucinogen psilocybin on habituation and prepulse inhibition of the startle reflex in humans. Behav Pharmacol9: 561–566.
50.
Gouzoulis-MayfrankESchreckenbergerMSabriO, et al. (1999) Neurometabolic effects of psilocybin, 3, 4-methylenedioxyethylamphetamine (MDE) and d-methamphetamine in healthy volunteers: A double-blind, placebo-controlled PET study with [18F] FDG. Neuropsychopharmacology20: 565–581.
51.
GrantBFGoldsteinRBSahaTD, et al. (2015) Epidemiology of DSM-5 alcohol use disorder: Results from the National Epidemiologic Survey on Alcohol and Related Conditions III. JAMA Psychiatry72: 757–766.
52.
GriffithsRRJohnsonMWRichardsWA, et al. (2011) Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects. Psychopharmacology218: 649–665.
53.
GriffithsRRJohnsonMWCarducciMA, et al. (2016) Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial. J Psychopharmacol30: 1181–1197.
54.
GriffithsRRRichardsWAJohnsonMW, et al. (2008) Mystical-type experiences occasioned by psilocybin mediate the attribution of personal meaning and spiritual significance 14 months later. J Psychopharmacol22: 621–632.
55.
GriffithsRRRichardsWAMcCannU, et al. (2006) Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance. Psychopharmacology187: 268–283.
56.
GrobCSDanforthALChopraGS, et al. (2011) Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer. Arch Gen Psychiatry68: 71–78.
57.
HalpernJHSherwoodARPassieT, et al. (2008) Evidence of health and safety in American members of a religion who use a hallucinogenic sacrament. Med Sci Monit14: SR15–SR22.
58.
HartogsohnI (2016) Set and setting, psychedelics and the placebo response: An extra-pharmacological perspective on psychopharmacology. J Psychopharmacol30: 1259–1267.
59.
HartogsohnI (2017) Constructing drug effects: A history of set and setting. Drug Sci Policy Law3: 1–17.
60.
HasinDSSarvetALMeyersJL, et al. (2018) Epidemiology of adult DSM-5 major depressive disorder and its specifiers in the United States. JAMA Psychiatry75: 336–346.
61.
HendricksPSThorneCBClarkCB, et al. (2015) Classic psychedelic use is associated with reduced psychological distress and suicidality in the United States adult population. J Psychopharmacol29: 280–288.
62.
HermleLFünfgeldMOepenG, et al. (1992) Mescaline-induced psychopathological, neuropsychological, and neurometabolic effects in normal subjects: Experimental psychosis as a tool for psychiatric research. Biol Psychiatry32: 976–991.
63.
HermleLGouzoulis-MayfrankESpitzerM (1998) Blood flow and cerebral laterality in the mescaline model of psychosis. Pharmacopsychiatry31: 85–91.
64.
HillTW (1990) Peyotism and the control of heavy drinking: The Nebraska Winnebago in the early 1900s. Hum Org255–265.
65.
HollisterLESheltonJKriegerG (1969) A controlled comparison of lysergic acid diethylamide (LSD) and dextroamphetamine in alcoholics. Am J Psychiatry125: 1352–1357.
66.
HongHKimBSImHI (2016) Pathophysiological role of neuroinflammation in neurodegenerative diseases and psychiatric disorders. Int Neurourol J 20(Suppl 1): S2–S7.
67.
HudziakJJHelzerJEWetzelMW, et al. (1993) The use of the DSM-III-R Checklist for initial diagnostic assessments. Compr Psychiatry34: 375–383.
68.
IBM Corporation (2016) IBM SPSS Statistics for Windows, Version 24.0. Armonk, NY: IBM Corp.
69.
JohnsonMWGarcia-RomeuACosimanoMP, et al. (2014) Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction. J Psychopharmacol28: 983–992.
70.
JohnsonMWGarcia-RomeuAGriffithsRR (2017a) Long-term follow-up of psilocybin-facilitated smoking cessation. Am J Drug Alcohol Abuse43: 55–60.
71.
JohnsonMWGarcia-RomeuAJohnsonPS, et al. (2017b) An online survey of tobacco smoking cessation associated with naturalistic psychedelic use. J Psychopharmacol31: 841–850.
72.
JohnsonMWGriffithsRRHendricksPS, et al. (2018) The abuse potential of medical psilocybin according to the 8 factors of the Controlled Substances Act. Neuropharmacology142: 143–166.
73.
JohnsonMWRichardsWAGriffithsRR (2008) Human hallucinogen research: Guidelines for safety. J Psychopharmacol22: 603–620.
74.
JohnstonLDO’MalleyPMBachmanJG, et al. (2016) Monitoring the Future National Survey Results on Drug Use, 1975–2015: Volume II, College Students and Adults Ages. Ann Arbor: MI: Institute for Social Research, pp. 19–55.
75.
JonasDEGarbuttJCAmickHRBrownJM, et al. (2012) Behavioral counseling after screening for alcohol misuse in primary care: A systematic review and meta-analysis for the US Preventive Services Task Force. Ann Int Med157: 645–654.
76.
JørgensenCHPedersenBTønnesenH (2011) The efficacy of disulfiram for the treatment of alcohol use disorder. Alcohol Clin Exp Res35: 1749–1758.
77.
KellyJFStoutRLMagillM, et al. (2011) Spirituality in recovery: A lagged mediational analysis of Alcoholics Anonymous’ principal theoretical mechanism of behavior change. Alcohol Clin Exp Res35: 454–463.
78.
KimYKNaKSMyintAM, et al. (2016) The role of pro-inflammatory cytokines in neuroinflammation, neurogenesis and the neuroendocrine system in major depression. Progr Neuro Psychopharmacol Biol Psychiatry64: 277–284.
79.
KometerMSchmidtABachmannR, et al. (2012) Psilocybin biases facial recognition, goal-directed behavior, and mood state toward positive relative to negative emotions through different serotonergic subreceptors. Biol Psychiatry72: 898–906.
80.
KraehenmannRPrellerKHScheideggerM, et al. (2015) Psilocybin-induced decrease in amygdala reactivity correlates with enhanced positive mood in healthy volunteers. Biol Psychiatry78: 572–581.
81.
KraehenmannRSchmidtAFristonK, et al. (2016) The mixed serotonin receptor agonist psilocybin reduces threat-induced modulation of amygdala connectivity. NeuroImage Clin11: 53–60.
82.
KrebsTSJohansenPØ (2012) Lysergic acid diethylamide (LSD) for alcoholism: Meta-analysis of randomized controlled trials. J Psychopharmacol26: 994–1002.
83.
KurlandAAUngerSShafferJW, et al. (1967) Psychedelic therapy utilizing LSD in the treatment of the alcoholic patient: A preliminary report. Am J Psychiatry123: 1202–1209.
84.
LaiHMXClearyMSitharthanT, et al. (2015) Prevalence of comorbid substance use, anxiety and mood disorders in epidemiological surveys, 1990–2014: A systematic review and meta-analysis. Drug Alcohol Depend154: 1–13.
85.
LattinD (2012) Distilled Spirits: Getting High, Then Sober, with a Famous Writer, a Forgotten Philosopher, and a Hopeless Drunk. Berkeley, CA: University of California Press.
86.
LiechtiMEDolderPCSchmidY (2017) Alterations of consciousness and mystical-type experiences after acute LSD in humans. Psychopharmacology234: 1499–1510.
87.
LudwigALevineJStarkL, et al. (1969) A clinical study of LSD treatment in alcoholism. Am J of Psychiatry126: 59–69.
88.
MacLeanKAJohnsonMWGriffithsRR (2011) Mystical experiences occasioned by the hallucinogen psilocybin lead to increases in the personality domain of openness. J Psychopharmacol25: 1453–1461.
89.
MacLeanKALeoutsakosJMSJohnsonMW, et al. (2012) Factor analysis of the mystical experience questionnaire: A study of experiences occasioned by the hallucinogen psilocybin. J Sci Study Relig51: 721–737.
90.
MaiselNCBlodgettJCWilbournePL, et al. (2013) Meta-analysis of naltrexone and acamprosate for treating alcohol use disorders: When are these medications most helpful?Addiction108: 275–293.
91.
MajićTSchmidtTTGallinatJ (2015) Peak experiences and the afterglow phenomenon: When and how do therapeutic effects of hallucinogens depend on psychedelic experiences?J Psychopharmacol29: 241–253.
92.
ManginiM (1998) Treatment of alcoholism using psychedelic drugs: A review of the program of research. J Psychoactive Drugs30: 381–418.
93.
MartinGWRehmJ (2012) The effectiveness of psychosocial modalities in the treatment of alcohol problems in adults: A review of the evidence. Can J Psychiatry57: 350–358.
94.
MillerWR (1998) Researching the spiritual dimensions of alcohol and other drug problems. Addiction93: 979–990.
95.
MillerWR (2004) The phenomenon of quantum change. J Clin Psychol60: 453–460.
96.
MillerWRC’de BacaJ (2001) Quantum Change: When Epiphanies and Sudden Insights Transform Ordinary Lives. New York, NY: Guilford Press.
97.
MillerWRWaltersSTBennettME (2001) How effective is alcoholism treatment in the United States?J Stud Alcohol62: 211–220.
98.
MoyerVA (2013) Screening and behavioral counseling interventions in primary care to reduce alcohol misuse: US Preventive Services Task Force recommendation statement. Ann Int Med159: 210–218.
99.
MuellerFLenzCDolderPC, et al. (2017) Acute effects of LSD on amygdala activity during processing of fearful stimuli in healthy subjects. Transl Psychiatry7: e1084.
100.
MuthénLKMuthénB (1998–2017) Mplus User’s Guide: Statistical Analysis with Latent Variables. Los Angeles, CA: Authors.
101.
NicholsDEJohnsonMWNicholsCD (2017) Psychedelics as medicines: An emerging new paradigm. Clin Pharmacol Ther101: 209–219.
102.
NielsonEMMayDGForcehimesAA, et al. (2018) The psychedelic debriefing in alcohol dependence treatment: Illustrating key change phenomena through qualitative content analysis of clinical sessions. Front Pharmacol9: 132.
103.
NuttDJKingLANicholsDE (2013) Effects of Schedule I drug laws on neuroscience research and treatment innovation. Nat Rev Neurosci14: 577.
104.
Oliveira-LimaAJSantosRHollaisAW, et al. (2015) Effects of ayahuasca on the development of ethanol-induced behavioral sensitization and on a post-sensitization treatment in mice. Physiol Behav142: 28–36.
105.
OsmondHAlbaharyRCheekF, et al. (1967) Some problems in the use of LSD 25 in the treatment of alcoholism. In: AbramsonHA (ed) The Use of LSD in Psychotherapy and Alcoholism. Indianapolis, IN: Bobbs-Merrill, pp. 434–457.
106.
PahnkeWNKurlandAAUngerS, et al. (1970) The experimental use of psychedelic (LSD) psychotherapy. JAMA212: 1856–1863.
107.
Palhano-FontesFAndradeKCTofoliLF, et al. (2015) The psychedelic state induced by ayahuasca modulates the activity and connectivity of the default mode network. PLoS One10: e0118143.
108.
Palhano-FontesFBarretoDOniasH, et al. (2019) Rapid antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression: A randomized placebo-controlled trial. Psychol Med49(4): 655–663.
109.
PidermanKMSchneeklothTDPankratzVS, et al. (2008) Spirituality during alcoholism treatment and continuous abstinence for one year. Int J Psychiatry Med38: 391–406.
110.
PrellerKHPokornyTHockA, et al. (2016) Effects of serotonin 2A/1A receptor stimulation on social exclusion processing. Proc Natl Acad Sci113: 5119–5124.
111.
PrueB (2013) Indigenous supports for recovery from alcoholism and drug abuse: The Native American Church. J Ethn Cult Divers Soc Work22: 271–287.
112.
ReinertDFAllenJP (2002) The alcohol use disorders identification test (AUDIT): a review of recent research. Alcohol Clin Exp Res26: 272–279.
113.
RosemanLNuttDJCarhart-HarrisRL (2017) Quality of acute psychedelic experience predicts therapeutic efficacy of psilocybin for treatment-resistant depression. Front Pharmacol8: 974.
114.
RossS (2012) Serotonergic hallucinogens and emerging targets for addiction pharmacotherapies. Psychiatr Clin35: 357–374.
115.
RossSBossisAGussJ, et al. (2016) Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: A randomized controlled trial. J Psychopharmacol30:1165–1180.
116.
RyanRMPlantRWO’MalleyS (1995) Initial motivations for alcohol treatment: Relations with patient characteristics, treatment involvement, and dropout. Addict Behav20: 279–297.
SaitzR (2010) Alcohol screening and brief intervention in primary care: Absence of evidence for efficacy in people with dependence or very heavy drinking. Drug Alcohol Rev29: 631–640.
121.
SaundersJBAaslandOGBaborTF, et al. (1993) Development of the alcohol use disorders identification test (AUDIT): WHO collaborative project on early detection of persons with harmful alcohol consumption-II. Addiction88: 791–804.
122.
SavageCMcCabeOL (1973) Residential psychedelic (LSD) therapy for the narcotic addict: A controlled study. Arch Gen Psychiatry28: 808–814.
123.
SchmidYLiechtiME (2018) Long-lasting subjective effects of LSD in normal subjects. Psychopharmacology235: 535–545.
124.
SellersEMLeidermanDB (2018) Psychedelic drugs as therapeutics: No illusions about the challenges. Clin Pharmacol Ther103: 561–564.
125.
SessaB (2018) Why MDMA therapy for alcohol use disorder? And why now?Neuropharmacology142: 83–88.
126.
SessaBJohnsonMW (2015) Can psychedelic compounds play a part in drug dependence therapy?Br J Psychiatry206: 1–3.
127.
SmartRGStormTBakerEF, et al. (1966) A controlled study of lysergide in the treatment of alcoholism. 1. The effects on drinking behavior. Quart J Stud Alcohol27: 469–482.
128.
SmithCM (1958) A new adjunct to the treatment of alcoholism: The hallucinogenic drugs. Quart J Stud Alcohol19: 406–417.
129.
SmithCM (1959) Some reflections on the possible therapeutic effects of the hallucinogens; with special reference to alcoholism. Quart J Stud Alcohol20: 292–301.
130.
SpitzerMThimmMHermleL, et al. (1996) Increased activation of indirect semantic associations under psilocybin. Biol Psychiatry39: 1055–1057.
131.
StahreMRoeberJKannyD, et al. (2014) Contribution of excessive alcohol consumption to deaths and years of potential life lost in the United States. Prev Chronic Dis11: E109. doi: 10.5888/pcd11.130293
132.
StrassmanRJQuallsCR (1994) Dose-response study of N, N-dimethyltryptamine in humans: I. Neuroendocrine, autonomic, and cardiovascular effects. Arch Gen Psychiatry51: 85–97.
133.
StrassmanRJQuallsCRUhlenhuthEH, et al. (1994) Dose-response study of N, N-dimethyltryptamine in humans: II. Subjective effects and preliminary results of a new rating scale. Arch Gen Psychiatry51: 98–108.
134.
StroudJBFreemanTPLeechR, et al. (2018) Psilocybin with psychological support improves emotional face recognition in treatment-resistant depression. Psychopharmacology235: 459–466.
135.
Substance Abuse and Mental Health Services Administration (SAMHSA) and National Institute on Alcohol Abuse and Alcoholism (NIAAA) (2015) Medication for the Treatment of Alcohol Use Disorder: A Brief Guide. HHS Publication No. (SMA) 15-4907. Rockville, MD: Substance Abuse and Mental Health Services Administration.
136.
TagliazucchiECarhart-HarrisRLeechR, et al. (2014) Enhanced repertoire of brain dynamical states during the psychedelic experience. Hum Brain Mapp35: 5442–5456.
137.
ThomasGLucasPCaplerNR, et al. (2013) Ayahuasca-assisted therapy for addiction: Results from a preliminary observational study in Canada. Curr Drug Abuse Rev6: 30–42.
138.
TomsovicMEdwardsRV (1970) Lysergide treatment of schizophrenic and nonschizophrenic alcoholics: A controlled evaluation. Quart J Stud Alcohol31: 932–949.
139.
TupperKWWoodEYensenR, et al. (2015) Psychedelic medicine: A re-emerging therapeutic paradigm. CMAJ187: 1054–1059.
UthaugMVvan OorsouwKKuypersKPC, et al. (2018) Sub-acute and long-term effects of ayahuasca on affect and cognitive thinking style and their association with ego dissolution. Psychopharmacol235: 2979–2989.
142.
VaillantGE (2003) A 60-year follow-up of alcoholic men. Addiction98: 1043–1051.
143.
Vargas-PerezHGriederTETing-A-KeeR, et al. (2017) A single administration of the hallucinogen, 4-acetoxy-dimethyltryptamine, prevents the shift to a drug-dependent state and the expression of withdrawal aversions in rodents. Eur J Neurosci45: 1410–1417.
144.
VasilakiEIHosierSGCoxWM (2006) The efficacy of motivational interviewing as a brief intervention for excessive drinking: A meta-analytic review. Alcohol Alcohol41: 328–335.
145.
VollenweiderFXLeendersKLScharfetterC, et al. (1997) Positron emission tomography and fluorodeoxyglucose studies of metabolic hyperfrontality and psychopathology in the psilocybin model of psychosis. Neuropsychopharmacology16:357–372.
146.
WeissRDO’MalleySSHoskingJD, et al. (2008) Do patients with alcohol dependence respond to placebo? Results from the COMBINE Study. J Stud Alcohol Drugs69: 878–884.
147.
WinstockARKaarSBorschmannR (2014) Dimethyltryptamine (DMT): Prevalence, user characteristics and abuse liability in a large global sample. J Psychopharmacol28: 49–54.
148.
World Health Organization (WHO) (2018) Management of Substance Abuse Unit: Global Status Report on Alcohol and Health, 2018. Geneva: World Health Organization.
